Smad3 Specific Inhibitor, Naringenin, Decreases the Expression of Extracellular Matrix Induced by TGF-β1 in Cultured Rat Hepatic Stellate Cells

Xingjun Liu,Wei Wang,Han Hu,Ning Tang,Chunling Zhang,Wei Liang,Minwei Wang
DOI: https://doi.org/10.1007/s11095-005-9043-5
IF: 4.58
2006-01-01
Pharmaceutical Research
Abstract:PurposeDuring the process of liver fibrogenesis, transforming growth factor-β (TGF-β) plays an essential role in modulating extracellular matrix (ECM) gene expression, and a growing body of evidence suggests that this is a Smad3-dependent process in the activated hepatic stellate cells (HSCs). Naringenin showed a significantly protective effect on experimental rat liver fibrosis, in our efforts to elucidate its antifibrosis molecular mechanisms and to find a novel target based on Smad3 signaling for challenging fibrosis diseases.MethodsIn this study, reverse transcription-polymerase chain reaction and Western blot assays were used to investigate the inhibitory effect of naringenin on ECM formation induced by TGF-β1 in the HSC-T6 cells.ResultsNaringenin reduced not only the accumulation of ECM, including collagen Iα1 (Col Iα1), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1), but also the production of Smad3 induced by TGF-β1 in both mRNA and protein levels in a dose-dependent manner. Moreover, naringenin selectively inhibited the transcription of Smad3, but not other Smads involved in TGF-β1 signaling pathways.ConclusionOur data demonstrate that naringenin can exert antifibrogenic effects by directly or indirectly down-regulating Smad3 protein expression and phosphorylation through TGF-β signaling.
pharmacology & pharmacy,chemistry, multidisciplinary
What problem does this paper attempt to address?